Regulatory Updates Analysis
🇺🇸 FDAExpert commentary and market intelligence for pharma strategy teams
Showing 1–12 of 61 articles
FDA Calendar 2026: Key Approval Dates and PDUFA Insights
This article outlines the upcoming FDA approval dates and PDUFA deadlines for 2026, providing essential insights for investors and analysts in the biopharma sector.
Oligonucleotide Therapeutics Market Size Report 2033: Clinical Trials Insights
This article provides an in-depth analysis of the Oligonucleotide Therapeutics market size for 2033, focusing on clinical trials and their implications for stakeholders.
NSF Announces Fourth Annual Pharma Biotech Conference 2026: Key Insights
The NSF's fourth annual Pharma Biotech Conference 2026 will address critical developments in clinical trials. This article provides key insights and implications for business development teams, investors, and analysts.
Biotech IPOs Surge Amid M&A Activity: A New Era
The biotech landscape is witnessing a resurgence in IPOs, driven by a wave of mergers and acquisitions. This article analyzes the implications for investors and pharma teams.
Mirum Maps FDA Path After Anti-Itch Candidate Scores Phase 2 Win
Mirum's recent Phase 2 trial success for its anti-itch candidate marks a significant step towards FDA approval, impacting oncology strategies. This analysis explores the implications for investors and pharma teams.
FDA Grants Early Access to Promising Drug for Pancreatic Cancer
The FDA has granted early access to a promising new drug for pancreatic cancer, marking a significant milestone in oncology. This analysis explores the implications for investors and pharma teams.
FDA Approves Expanded Access for Daraxonrasib in Pancreatic Cancer
The FDA has approved expanded access for Daraxonrasib in pancreatic cancer, presenting new opportunities for patients and investors alike. This article explores the implications of this approval for the pharmaceutical landscape.
FDA Approval for Datroway: Implications for Breast Cancer Treatment
The FDA has granted approval for Datroway, a significant development for breast cancer treatment by Daiichi Sankyo and AstraZeneca. This article explores the implications for investors and pharma teams.
Five Key Regulatory Updates to Watch at ASCO
This article highlights five crucial regulatory updates at ASCO, particularly focusing on Daraxonrasib and its potential impact on the pharmaceutical landscape.
Palvella Secures $230M to Advance QTORIN for Rare Diseases
Palvella Therapeutics has raised $230 million to support the NDA for QTORIN, targeting rare diseases. This funding positions the company for significant growth.
First RAS Inhibitor Extends Survival in Metastatic Pancreatic Cancer
Daraxonrasib, the first RAS inhibitor, has received FDA approval, extending survival in metastatic pancreatic adenocarcinoma. This article outlines key updates and implications for stakeholders.
BioMarin Seeks Approval for Voxzogo in Short Stature Indication
BioMarin Pharmaceutical is pursuing further approval for Voxzogo to treat short stature. This article explores the implications for investors and pharma teams.